<DOC>
	<DOCNO>NCT02465216</DOCNO>
	<brief_summary>The purpose study evaluate safety immunogenicity ID93 + GLA-SE vaccine administer adult pulmonary Tuberculosis ( TB ) patient , follow successful completion TB treatment confirm bacteriologic cure , preparation future Phase 2b prevention TB recurrence trial population .</brief_summary>
	<brief_title>Phase 2a ID93 + GLA-SE Vaccine Trial TB Patients After Treatment Completion</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Pulmonary</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Males females 18 60 year age . 2 . Subjects must successfully treat , i.e. , complete scheduled course TB treatment per prevail South African national guideline , MTB cultureconfirmed , drug sensitive pulmonary TB , evidence record positive liquid MTB culture formal drug sensitivity test ( DST ) and/or Xpert MTB/RIF test baseline . 3 . Must two separate sample show bacteriologic confirmation cure define first instance Xpert MTB/RIF test negative , , Xpert MTB/RIF positive , MTB liquid culture negative two successive occasion least 30 day apart . Subjects sputum unproductive deem Xpert MTB/RIF MTB liquid culture negative . 4 . Female subject childbearing potential must negative serum pregnancy test screen negative urine pregnancy test day study injection , must breastfeed , willing avoid pregnancy 3 month follow first study injection . Women physically capable pregnancy ( sterilize still menstruate within 1 year last menses menopausal ) sexual relationship men must use acceptable method avoid pregnancy period . Acceptable method avoid pregnancy include sterile sexual partner , sexual abstinence ( engage sexual intercourse ) , hormonal contraceptive ( oral , injection , transdermal patch , implant ) , vaginal ring , intrauterine device ( IUD ) , combination condom diaphragm spermicide gel . 5 . The follow screening laboratory value must within laboratory reference range , abnormal , deem clinically significant less Grade 2 severity FDA Toxicity Scale , determine PI LMM Sponsor Medical Advisor : ALT , AST , total bilirubin , creatinine , total WBC count , hemoglobin , platelet count . 6 . The HIV 1/2 antibody serology test must negative . 7 . Must give informed consent , able willing make evaluation visit , reachable telephone personal contact study site personnel , willing remain study area duration trial . 1 . TB treatment failure , evidence clinical diagnosis positive MTB liquid culture month 4 5 start treatment . A positive MTB liquid culture , , end treatment would exclude subject receive study injection . 2 . Previous course TB treatment complete within 5 calendar year prior obtain baseline diagnostic sputum sample . 3 . Receipt investigational product investigational drug past 6 month investigational vaccine ever . 4 . Treatment immunosuppressive drug ( e.g. , oral injected steroid , prednisone ; high dose inhaled steroid ) past 6 month . Topical steroid would allowable . 5 . Received incomplete investigational , nonstandard TB drug regimen , prevail current South African national guideline reference standard , poor adherence TB treatment regimen . 6 . Diagnosed rifampicinresistant MTB strain ( Xpert MTB/RIF and/or culture formal DST ) . 7 . History autoimmune disease cause immunosuppressive state . 8 . History evidence acute chronic illness ( include diabetes mellitus , asthma ) , medical surgical condition , chronic heavy ethanol drug use , use medication , opinion Principal Investigator , may interfere evaluation safety immunogenicity vaccine . 9 . Subjects history previous anaphylaxis severe allergic reaction vaccine , egg , unknown allergen . 10 . Subjects unlikely cooperate requirement study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Tuberculosis</keyword>
	<keyword>TB</keyword>
	<keyword>Pulmonary</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Adjuvant</keyword>
</DOC>